14-day Premium Trial Subscription Try For FreeTry Free
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in

The 2 Best ETFs for Dividends

02:45pm, Monday, 28'th Feb 2022 The Motley Fool
These two ETFs are built to deliver the most dividend income possible

Organon Shares Up About 7% Since Merck Spinoff

02:51pm, Thursday, 24'th Feb 2022
Shares of Organon & Co. ( OGN , Financial) are up nearly 7% since the pharma company was spun off by Merck & Co. Inc. ( MRK , Financial) in the middle of 2021. And even bluer skies appear to be on the
Viatris was formed by the merger of Pfizer's Legacy Brands business Upjohn with generic drug developer Mylan.

Organon & Co. 2022 Q4 - Results - Earnings Call Presentation

04:47pm, Thursday, 17'th Feb 2022 Seeking Alpha

Merck Spinoff Organon Beats Quarterly Views, But Offers Dim Guidance

02:03pm, Thursday, 17'th Feb 2022 Investor''s Business Daily
Organon topped fourth-quarter estimates Thursday, but OGN stock fell on lighter-than-expected 2022 sales guidance.
Organon & Co. (OGN) CEO Kevin Ali on Q4 2021 Results - Earnings Call Transcript
Organon & Co''s (NYSE: OGN ) Q4 FY21 sales decreased 1% to $1.6 billion , beating the consensus of $1.57 billion. Women''s Health increased 6%, driven primarily by Nexplanon, which increased 37% ex-FX. Nexplanon''s growth was due to increased demand in the U.S., and tenders won. The increase in Women''s Health was partially offset by a decline … Full story available on Benzinga.com

Organon declares $0.28 dividend

12:38pm, Thursday, 17'th Feb 2022 Seeking Alpha
Organon (OGN) declares $0.28/share quarterly dividend, in line with previous…......................
Organon (OGN) set its 2022 revenue in line with Wall Street forecasts even as the contraction in its topline and the bottom line continued for another quarter in Q4 2021
Organon press release (OGN): Q4 Non-GAAP EPS of $1.37 beats by $0.10.Revenue of $1.6B (-0.6% Y/Y) beats by $20M.FY22 Guidance:Revenue of $6.1-$6.4B vs
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon reports results for the fourth quarter and full year ended December 31, 2021

Earnings Scheduled For February 17, 2022

10:02am, Thursday, 17'th Feb 2022 Benzinga
Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.
Organon & Co's (NYSE: OGN) Q4 FY21 sales decreased 1% to $1.6 billion, beating the consensus of $1.57 billion. Women's Health increased 6%, driven primarily by Nexplanon, which increased 37% ex-FX.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE